期刊文献+

慢性丙型肝炎患者外周血CTLA-4的表达及其临床意义 被引量:1

Expression and clinical significance of CTLA- 4 in peripheral blood of patients with chronic hepatitis C
原文传递
导出
摘要 目的探讨慢性丙型肝炎患者外周血CTLA-4的变化规律及其临床意义。方法纳入55例慢性丙型肝炎患者和41例健康对照者,分离外周血单个核细胞,应用ⅣI’-PCR法检测CTLA-4mRNA相对表达水平;采用荧光定量RT.PCR检测HCVRNA。结果慢性丙型肝炎患者外周CTLA-4mRNA水平是健康对照组的3.47倍,差异有统计学意义(P〈0.05)。HCV1b基因型患者CTLA-4mRNA水平较2a基因型分别升高3.8l倍,差异有统计学意义(P〈0.05)。丙氨酸氨基转移酶(ATJT)〉3ULN组和天门冬氨酸氨基转移酶(AST)〉3ULN组患者CTLA.4mRNA水平分别显著低于ALT〈3ULN和AST〈3ULN组(P:0.026〈0.05)。结论HCV感染者机体处于一定的免疫耐受状态,HCV1b基因型的患者机体处于较强的免疫耐受状态,T细胞反应性较低。CTLA4表达水平降低可以启动炎症反应并加重慢性丙肝者肝细胞损伤。CTLA-4可能在HCV感染慢性化中发挥重要作用。 Objective To investigate the changes and clinical significance of peripheral blood CTLA-4 in patients with chronic hepatitis C. Methods Fifty-five patients with chronic hepatitis C and 41 healthy control were enrolled in this study. Peripheral blood monouelear cells (PBMC)were isolated. The related mRNA expressions of CTLA-4 were measured by RT-PCR;HCV RNA was detected by real- time RT-PCR. Results The level of CTLA-4 mRNA increased in chronic hepatitis C, with 3.47-time higher than those in healthy controls. The expression of CTLA-4 mRNA significantly increased in HCV genotype lb than those in HCV genotype 2a,with 3.81-time higher(P 〈 0. 05). The levels of CTLA-4 mRNA increased in patients with ALT and AST more than 3 upper normal levels ( P = 0.026 〈 0.05 ). Conclusions HCV infection result in immunologic tolerance, which is more severe in HCV genotype 1 b. It is possible that the decrease expression of CTLA-4 gene would start inflammatory response and fa- vour persistent hepatocellular lesion in chronic hepatitis C. CTLA-4 may take part in the immune toler- ance induced by the HCV infection and play an important role in chronic HCV infection.
出处 《中国实用医刊》 2013年第22期28-30,共3页 Chinese Journal of Practical Medicine
关键词 CTLA-4 慢性丙型肝炎 免疫耐受 CTLA-4 Chronic hepatitis C Immunologic tolerance
  • 相关文献

参考文献8

  • 1Salomon B, Bluestone JA. Complexities of CD28/ B7 : CTLA24 cos- timulatory pathways in autoimmunity and transplantation E J ]- Annu Rev Immunol, 2001,19 ( 1 ) :225-252. 被引量:1
  • 2毛海婷,王雄彪,张玲,顾洪涛.CTLA-4基因多态性在重症肌无力发病机理中的作用[J].中华医学遗传学杂志,2004,21(6):574-578. 被引量:13
  • 3Kantarci OH, Hebrink DD, Achenbach SJ, et al. CTLA24 is associ- ated with susceptibility to multiple sclerosis [ J ]. J Neuroimmunol, 2003,134(122) :133-141. 被引量:1
  • 4丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 5Oosterwegel MA, Greenwald RJ, Mandelbrot DA, et at. CTLA4 and T cell activation[J]. Curr Opin Immunol, 1999,11 (3) : 294-300. 被引量:1
  • 6hose I, Kanto T, Kakita N, et al. Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis [ J ]. J Viral Hepat, 2009,16 (12) : 844-852. 被引量:1
  • 7Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C : an update [ J ]. Hepatology,2009, 49 (4) : 1335-1374. 被引量:1
  • 8Manns MP, Mchutehison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [ J ]. Lancet, 2001, 358(9286) : 958-965. 被引量:1

二级参考文献16

  • 1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869. 被引量:1
  • 2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698. 被引量:1
  • 3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155. 被引量:1
  • 4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18. 被引量:1
  • 5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137. 被引量:1
  • 6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12. 被引量:1
  • 7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144. 被引量:1
  • 8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214. 被引量:1
  • 9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081. 被引量:1
  • 10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20. 被引量:1

共引文献746

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部